To the Editor We read with interest the article by Suntharalingam et al1 demonstrating that the addition of cetuximab to concurrent chemoradiation therapy did not improve overall survival in the nonoperative treatment of patients with esophageal cancer. Although the study stratified patients according to tumor histologic type, it was not powered to assess with certainty the benefit of cetuximab therapy in each of the 2 main histological variants of this disease.
Liu J, Yue J. Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. JAMA Oncol. 2018;4(6):887. doi:10.1001/jamaoncol.2018.0228
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: